Personalized Peptide-Based Vaccination against Acinetobacter baumannii

A next-generation vaccination system that leverages genotyping, peptide-based vaccines, and nanoparticle delivery to provide personalized protection against Acinetobacter baumannii

The original patent disclosed novel proteins and polynucleotides derived from Acinetobacter baumannii, but its limitation lies in the lack of personalization and adaptability to individual immune responses. The new inventive concept addresses this limitation by introducing a system that can identify an individual's specific immune response profile and tailor a vaccine formulation accordingly

The inventive concept comprises a microarray-based genotyping platform that analyzes an individual's genetic variability to identify their specific immune response profile. This information is then used to formulate a peptide-based vaccine tailored to the individual's profile. The vaccine is delivered via a nanoparticle-based system that targets specific immune cells, enhancing the immune response. The system also includes a diagnostic kit for rapid detection of Acinetobacter baumannii infections

The new inventive concept introduces a paradigm shift in vaccination by incorporating genotyping, personalized peptide-based vaccines, and nanoparticle delivery. This combination of technologies is new and non-obvious compared to the original patent, which focused on pharmaceutical compositions and adjuvants

Alternative embodiments of the inventive concept could include the use of different genotyping platforms, such as next-generation sequencing, or the incorporation of additional adjuvants to enhance the immune response. Variations could also include the development of vaccines tailored to specific HLA types or immune response profiles

The inventive concept has significant commercial potential in the vaccine industry, particularly in the context of personalized medicine. Target markets could include hospitals, clinics, and research institutions, as well as pharmaceutical companies and biotech firms